Sara Naldini
Overview
Explore the profile of Sara Naldini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scarallo L, Banci E, De Blasi A, Paci M, Renzo S, Naldini S, et al.
J Pediatr Gastroenterol Nutr
. 2024 Jul;
79(3):592-601.
PMID: 38962891
Objectives: We aimed to appraise the real-life efficacy of Crohn's disease exclusion diet (CDED) coupled with partial enteral nutrition (PEN) in inducing clinical and biochemical remission at disease onset and...
2.
Barni S, Pessina B, Scarallo L, Renzo S, Pieri E, Labriola F, et al.
Clin Exp Allergy
. 2024 Jan;
54(3):225-227.
PMID: 38262705
No abstract available.
3.
Histological healing as a predictor of sustained clinical remission in paediatric ulcerative colitis
Scarallo L, Fioretti L, Paci M, Naldini S, Renzo S, Barp J, et al.
Dig Liver Dis
. 2023 Jul;
56(1):43-49.
PMID: 37455156
Background: The study aimed to assess the longitudinal impact of endoscopic healing (EH) and histological healing (HH) in a cohort of paediatric patients affected by ulcerative colitis (UC). Methods: This...
4.
Scarallo L, Bolasco G, Barp J, Bianconi M, Di Paola M, di Toma M, et al.
Inflamm Bowel Dis
. 2021 Apr;
28(2):183-191.
PMID: 33835155
Background: The aim of the present study was to investigate outcomes of anti-TNF-alpha (ATA) withdrawal in selected pediatric patients with inflammatory bowel disease who achieved clinical remission and mucosal and...
5.
Tapete G, Bertani L, Pieraccini A, Lynch E, Giannotta M, Morganti R, et al.
Inflamm Bowel Dis
. 2021 Feb;
28(1):62-69.
PMID: 33570142
Background: Few data are currently available about SB5 in inflammatory bowel diseases (IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort...
6.
Scarallo L, Alvisi P, Bolasco G, di Toma M, Lanari M, Cangiari A, et al.
J Pediatr Gastroenterol Nutr
. 2021 Jan;
72(5):728-735.
PMID: 33399329
Objectives: Mucosal healing (MH) and histological healing (HH) have been recently proposed as a novel treatment target for inflammatory bowel disease (IBD). The aim of the present study was to...
7.
Scarallo L, Maniscalco V, Paci M, Renzo S, Naldini S, Barp J, et al.
J Pediatr Gastroenterol Nutr
. 2020 Feb;
71(1):46-51.
PMID: 32102087
Background And Objective: Acute severe colitis (ASC) is a potentially life-threatening event. Optimal timing for second-line treatment in children is mainly based on the clinical score Pediatric Ulcerative Colitis Activity...
8.
Trippella G, Lionetti P, Naldini S, Peluso F, Monica M, Stagi S
Ital J Pediatr
. 2018 Nov;
44(1):138.
PMID: 30458885
Background: Trichorhinophalangeal syndrome (TRPS) is a rare autosomal dominant disorder caused by defects involving the TRPS1 gene. It exhibits distinctive craniofacial, ectodermal and skeletal abnormalities, such as sparse hair, bulbous...